Kenya Reference Regulatory Agencies: Recognition, Independence and the 510(k) Trap

Content verified as of October 30, 2026

1. Key takeaways

• Kenya recognizes 8 reference regulatory agencies: TGA (Australia), Health Canada, US FDA, EU Notified Bodies, MHLW (Japan), HPRA (Ireland), SFDA (Saudi Arabia) and Swiss Medic (Switzerland).
• Approvals from the EU and TGA count as independent reference approvals only where reviewed and approved by that authority itself and not registered under a mutual recognition agreement (MRA).
• The IBR provisions list 7 independent reference authorities by name: HC, MHLW, USFDA, TGA, EU NB, SWISSMEDIC and HPRA.
• US FDA approvals are accepted only on the 510(k) or PMA pathways; 510(k)-exempt products do not qualify for the abridged route.
• The count thresholds rise with risk class: Class B abridged requires at least 2, Class C/D abridged at least 3, and the second ECR gate at least 5.
• The legal basis is Section 3B(2)(r) of Cap. 244: PPB may recognize and rely on foreign decisions yet remains independently responsible for its decisions.

2. Legal basis

3. Expert insights

Insight 1: Reliance without surrendering the decision is the design at the bottom of the system

Section 3B(2)(r) reads in two movements: the first authorizes PPB to recognize and rely on the registrations and certifications of other countries, and the second immediately states that PPB remains independently responsible for its decisions. This is not verbal redundancy; it confines reliance to evidence reliance rather than conclusion reliance. A foreign approval may shorten the review, but it cannot make the registration decision in PPB’s place. Once that is understood, it follows why reference approvals must be products of independent review: only conclusions born of substantive review carry the evidentiary value that reliance presupposes.

Insight 2: Why MRA registrations do not count, on two levels

The first level is that a chain of reliance cannot be transferred twice. Under an MRA, the underlying review was performed by a third authority, so what PPB would be relying on is in fact the judgment of another party it has never verified, extending the reliance chain by one link. The second level is verifiability: PPB needs to trace the review basis of an approval, and MRA registration documents usually do not carry a full review record. For companies the impact is concrete. A product holding an EU CE certificate must confirm that the certificate was reviewed and issued by the EU Notified Bodies themselves rather than converted under an MRA; the same applies to TGA. GRZAN recommends making this confirmation a written record placed at the front of the reliance-route submission package.

Insight 3: The 510(k) exemption is a hidden eligibility trap

The guidelines are explicit: US FDA approvals count only on the 510(k) or PMA pathways, and 510(k)-exempt products do not qualify for the abridged route. The reason is that a 510(k) exemption means FDA performed no substantive premarket review of the product, so no review conclusion exists to be relied upon. Companies often assume that lawful sale in the United States equals an FDA approval, and then count exempt products toward the reference approval tally. The consequences of this misjudgment are most severe under immediate registration: the count is reached, the file is submitted, the product fails post-hoc verification, and the registration is revoked without refund.

Insight 4: What an acceptable evidence package looks like

An acceptable reference approval package contains at least four items: a copy of the approval certificate or letter, the approved label and scope-of-use text, the validity status of the approval, and proof of marketing of the product in that jurisdiction. The difference between the 7 and 8 authority counts tells companies that the enumeration of authorities is not identical across routes; before filing, check the authority list route by route rather than reusing the list from the previous submission. Certificate validity must also cover the submission date. Registration certificates are valid for 5 years from issue, and an expired reference approval is equally no basis for reliance.

4. Practical recommendations

1. Maintain a reference approval log. Record for each approval the authority, certificate number, approval pathway (510(k) or PMA, for example), scope, validity and first marketing date.
2. Confirm independence certificate by certificate. For EU and TGA certificates, obtain written confirmation of self-conducted review rather than MRA registration.
3. Exclude exempt products. Anything under FDA 510(k) exemption is not counted toward the reference approval tally.
4. Check the authority list against the route. Match the applicable authority list to the intended route (Abridged, EBR, IBR, ECR, EDR), noting the difference between 7 and 8.
5. Compare scope of use in parallel. The labeled use of each reference approval must match the intended market use; mismatches are handled under the abridged-route rules.
6. Link validity to annual retention. Set expiry alerts so the reliance basis does not lapse during review.

5. Verification checklist

• □ Do all reference approvals come from the 8 recognized authorities?
• □ Have EU and TGA approvals been confirmed as self-reviewed and not MRA registrations?
• □ Are FDA approvals on the 510(k) or PMA pathway, with no 510(k)-exempt products counted?
• □ Is each certificate still valid (normally 5 years)?
• □ Has the authority list applicable to the intended route been checked, including the 7-authority version?
• □ Does the labeled use of each reference approval match the intended market use?
• □ Is a written record of the independence confirmation attached to the submission package?
• □ Are the count thresholds met (2, 3 or 5)?

Regulatory information verified as of October 30, 2026.

Across African markets, the GRZAN regulatory team focuses on jurisdictions including Kenya, Nigeria, South Africa and Egypt, and operates a verification mechanism built on primary regulatory sources: every regulatory conclusion published externally rests solely on official gazettes, the original text of competent authority guidelines and public legal databases, each marked with its verification date. Any figure, timeline or amount that cannot be located in an official source is labeled as a practical estimate and never presented as an assumption.

GRZAN services cover market access strategy and risk classification assessment; preparation and review of registration dossiers in CSDT, STED and CTD formats; selection and management of Local Authorized Representatives (LAR); quality management system and GMP/GSDP compliance support; post-market vigilance, change management and recall response; import customs clearance and PVoC coordination; and regulatory intelligence subscription with corporate compliance record-keeping.

For a Kenya market access plan tailored to your specific product, contact the GRZAN regulatory team at info@grzanglobal.com.